Hvivo has been a client of Cryostore for over 20 years, representing 16 per cent of its revenue in 2024 ...
Hosted on MSN14d
hVIVO expands with German units acquisition for €10mThe two units reported unaudited revenues of €19.9 million for the year ended 31 December 2024, an increase from €18.6 million in 2023. hVIVO's full-year revenue guidance for 2025 is £73 ...
Boss Mark Read (pictured) said that although revenues were hit by weaker client discretionary spending, growth of 2% was seen ...
Hvivo anticipates that full-scale Hmpv human challenge trials (HCTs) could commence in the second half of 2025 ...
hVIVO is a specialist contract research organization (CRO) and a world leader in human challenge models. A human challenge trial overcomes the complexities associated with conducting traditional ...
Research firm HVIVO has announced that it hopes to commence the final stage of its study on human metapneumovirus (HMPV) ...
COEP Coeptis Therapeutics Holdings, Inc.
Pharmaceutical services firm hVivo, formerly Open Orphan, has acquired two clinical trial units in Germany from CRS Clinical Research Services Management GmbH for a cash consideration of €10m.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...
The UK market has faced challenges recently, with the FTSE 100 index closing lower due to weak trade data from China, highlighting concerns about global economic recovery. In such a climate ...
LONDON - hVIVO plc, a leading early-stage Contract Research Organisation (CRO) known for its human challenge clinical trials, has acquired two Clinical Research Units (CRUs) from CRS Clinical Research ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results